Elanco Animal Health INC Form 4 insider transactions

James M. Meer, Chief Accounting Officer of Elanco Animal Health Inc, reported the disposal of 2,356 shares of common stock on March 1, 2025.

Jose Manuel Correia de Simas, an Executive Vice President at Elanco Animal Health, disposed of 4,747 shares of common stock on March 1, 2025, to cover tax obligations.

Grace McArdle, EVP of Manufacturing and Quality at Elanco Animal Health, reports the disposal of 3,430 shares of common stock to cover tax obligations.

Ellen de Brabander, an Executive Vice President at Elanco Animal Health Inc, disposed of 15,049 shares of common stock on March 1, 2025, to satisfy tax withholding obligations.

Elanco Animal Health Inc. Executive Vice President Ramiro Martin Cabral disposed of 11,749 shares of common stock on March 1, 2025, to cover tax obligations.

David S. Kinard, Executive Vice President of Elanco Animal Health, reports a transaction involving common stock on March 1, 2025.

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units convertible to common stock, according to a Form 4 filing with the SEC.

James M. Meer, Chief Accounting Officer of Elanco Animal Health, reports acquisition of shares and a disposition to cover tax obligations, along with a correction to a previous filing.

David S. Kinard, an executive at Elanco Animal Health, reports the acquisition and disposal of company stock on February 19, 2025.

Elanco Animal Health's Executive Vice President, Ramiro Martin Cabral, reports the acquisition and disposal of company stock.

Todd S. Young, Executive Vice President and CFO of Elanco Animal Health, reports acquisition and disposal of company stock, resulting in adjusted beneficial ownership.

Jose Manuel Correia de Simas, an Executive Vice President at Elanco Animal Health, reported the acquisition and disposal of company stock on February 19, 2025.

Elanco Animal Health CEO Jeffrey Simmons reports acquisition and disposal of company stock, including corrections to previous filings and participation in the Employee Stock Purchase Plan.

EVP Grace McArdle reports acquisition of 8,025 shares and disposition of 2,596 shares of Elanco Animal Health Inc. common stock.

Ellen de Brabander, an Executive Vice President at Elanco Animal Health Inc, reported the acquisition and disposal of company stock on February 19, 2025.

Elanco Animal Health Inc. executive Rajeev A. Modi reports acquisition and disposal of common stock, resulting in adjustments to his beneficial ownership.

Shiv O'Neill, GC AND CORP SEC of Elanco Animal Health Inc, reports the acquisition and disposal of common stock on February 19, 2025.

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC Form 4 filing.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units on February 7, 2025.

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units on January 24, 2025.

Rajeev A. Modi, an executive at Elanco Animal Health, acquired deferred stock units representing the right to receive common stock or cash.

Elanco Animal Health's CEO, Jeffrey N. Simmons, reported the acquisition of deferred stock units convertible to common stock, according to a Form 4 filing with the SEC.

James M. Meer, Chief Accounting Officer of Elanco Animal Health, disposed of 414 shares of common stock on January 3, 2025.

Grace McArdle, EVP of Manufacturing and Quality at Elanco Animal Health, disposed of 351 shares of common stock on January 3, 2025.

Director Lawrence Kurzius reports acquisition of deferred stock units in Elanco Animal Health Inc. through a director deferral plan.

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired 229.6219 deferred stock units on December 27, 2024, convertible to common stock or cash.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, acquired deferred stock units representing the right to receive common stock or cash.

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired 228.8628 deferred stock units on December 13, 2024, which will convert to common stock or cash upon termination or at a future date.